Cite
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
MLA
Yoshioka, H., et al. “Final Overall Survival Results of WJTOG3405, a Randomized Phase III Trial Comparing Gefitinib versus Cisplatin with Docetaxel as the First-Line Treatment for Patients with Stage IIIB/IV or Postoperative Recurrent EGFR Mutation-Positive Non-Small-Cell Lung Cancer.” Annals of Oncology, vol. 30, no. 12, Dec. 2019, pp. 1978–84. EBSCOhost, https://doi.org/10.1093/annonc/mdz399.
APA
Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., & Mitsudomi, T. (2019). Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Annals of Oncology, 30(12), 1978–1984. https://doi.org/10.1093/annonc/mdz399
Chicago
Yoshioka, H, M Shimokawa, T Seto, S Morita, Y Yatabe, I Okamoto, J Tsurutani, et al. 2019. “Final Overall Survival Results of WJTOG3405, a Randomized Phase III Trial Comparing Gefitinib versus Cisplatin with Docetaxel as the First-Line Treatment for Patients with Stage IIIB/IV or Postoperative Recurrent EGFR Mutation-Positive Non-Small-Cell Lung Cancer.” Annals of Oncology 30 (12): 1978–84. doi:10.1093/annonc/mdz399.